Research library
Other NotablePreclinical / anecdotal
Long-R3-IGF-1
IGF-1 LR3, Long acting IGF-1 analog
A long acting IGF-1 analog engineered to evade binding proteins, driving IGF-1R signaling and muscle hypertrophy, with the steepest risk profile in this library.
20-30 h
IGF-1R
High
How IGF-1 LR3 works
A long acting IGF-1 redesigned to dodge the proteins that normally rein it in, maximizing muscle growth signaling, and with it the steepest risk profile in this library.
IGF-1 LR3
Evades IGFBPs
IGF-1R to PI3K/Akt
Hypertrophy
Research applications
Muscle hypertrophy
Bodybuilding use
Native IGF-1 (Increlex)
Severe IGF-1 deficiency
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Molecular profile
Evidence, safety & status
Claimed benefits & evidence
Marketed in bodybuilding for muscle growth. There are essentially no peer reviewed human trials of IGF-1 LR3 itself; all extrapolation is from native IGF-1 (FDA approved as Increlex only for severe primary IGF-1 deficiency).
Safety & dangers
The most concerning risk benefit on this list: hypoglycemia (can be severe), chronic insulin resistance, and a strong theoretical oncogenic risk, chronically elevated IGF-1 is epidemiologically linked to colorectal, breast, and prostate cancer. Long term high exposure can cause organ/intestinal growth (acromegaly like features).
Contraindications
Active or history of cancer; predisposition to malignancy; diabetes; pregnancy.
Regulatory status
Not FDA approved (the analog); sold as a research chemical, illegal for human use in the US/UK/EU. WADA prohibited (S2).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
For research use only
For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.